Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 12

1.

[(11)C]PR04.MZ, a promising DAT ligand for low concentration imaging: Synthesis, efficient (11)C-O-methylation and initial small animal PET studies.

Riss PJ, Hooker JM, Alexoff D, Kim SW, Fowler JS, Rösch F.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4343-5. doi: 10.1016/j.bmcl.2009.05.090. Epub 2009 May 28.

PMID:
19525112
2.

[11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET.

Saba W, Valette H, Schöllhorn-Peyronneau MA, Coulon C, Ottaviani M, Chalon S, Dolle F, Emond P, Halldin C, Helfenbein J, Madelmont JC, Deloye JB, Guilloteau D, Bottlaender M.

Synapse. 2007 Jan;61(1):17-23.

PMID:
17068778
3.

Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.

Chalon S, Hall H, Saba W, Garreau L, Dollé F, Halldin C, Emond P, Bottlaender M, Deloye JB, Helfenbein J, Madelmont JC, Bodard S, Mincheva Z, Besnard JC, Guilloteau D.

J Pharmacol Exp Ther. 2006 Apr;317(1):147-52. Epub 2005 Dec 9.

4.

Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET.

Dollé F, Emond P, Mavel S, Demphel S, Hinnen F, Mincheva Z, Saba W, Valette H, Chalon S, Halldin C, Helfenbein J, Legaillard J, Madelmont JC, Deloye JB, Bottlaender M, Guilloteau D.

Bioorg Med Chem. 2006 Feb 15;14(4):1115-25. Epub 2005 Oct 10.

PMID:
16219467
5.

Learning networks in health and Parkinson's disease: reproducibility and treatment effects.

Carbon M, Ghilardi MF, Feigin A, Fukuda M, Silvestri G, Mentis MJ, Ghez C, Moeller JR, Eidelberg D.

Hum Brain Mapp. 2003 Jul;19(3):197-211.

PMID:
12811735
6.

Dopamine transporter imaging with fluorine-18-FPCIT and PET.

Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, Neumeyer J, Eidelberg D.

J Nucl Med. 1998 Sep;39(9):1521-30.

7.

[18F] beta-CIT-FP is superior to [11C] beta-CIT-FP for quantitation of the dopamine transporter.

Lundkvist C, Halldin C, Ginovart N, Swahn CG, Farde L.

Nucl Med Biol. 1997 Oct;24(7):621-7.

PMID:
9352532
8.

Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography.

Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl JR, Belakhlef A, Margouleff D, Yee A, Wang S, Tamagnan G, Neumeyer JL, Eidelberg D.

Nucl Med Biol. 1996 Nov;23(8):999-1004.

PMID:
9004288
9.

SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT.

Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Laruelle M, Charney DS, Hoffer PB, Neumeyer JL, Innis RB.

J Nucl Med. 1996 Jul;37(7):1129-33.

10.

Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.

Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, Eidelberg D.

J Nucl Med. 1996 Nov;37(11):1760-5.

11.

Basal ganglia and movement disorders: an update.

Chesselet MF, Delfs JM.

Trends Neurosci. 1996 Oct;19(10):417-22. Review.

PMID:
8888518
12.

Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects.

Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, Neumeyer JL, Charney DS, Hoffer PB, Innis RB.

J Cereb Blood Flow Metab. 1994 Nov;14(6):982-94.

PMID:
7929662

Supplemental Content

Support Center